Satoreotide tetraxetan

Star0

DB16323InvestigationalSmall molecule

Satoreotide tetraxetan: Overview.

Mechanism: Pharmacologically active on Somatostatin receptor type 2 and Somatostatin receptor
Curator reviewed
Formula / weight: C₇₄H₉₈ClN₁₉O₂₁S₂ · 1689.28 g/mol (avg)
Also known as: Dota satoreotide · Satoreotide dota
Code names: DOTA-JR-11

Resolves to

Compound

UNIIEC1O2FB9FVCAS1039726-31-2

Structure

InChIKeyZJZDXGQUNVNYQP-PBJKGYOGSA-NSMILES

[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CC=C(NC(N)=O)C=C2)NC(=O)[C@H](CC2=CC=C(NC(=O)[C@@H]3CC(=O)NC(=O)N3)C=C2)NC(=O)[C@@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CC1=CC=C(O)C=C1)C(N)=O)NC(=O)[C@H](CC1=CC=C(Cl)C=C1)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)[C@@H](C)O

Targets

P30874SSTR2

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Satoreotide tetraxetan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account